Founded by scientists from Oregon Health and Science University, the most recent data on Znomics indicates the firm was acquired in October 2-13 by Williston Holding Company, Inc., in a reverse merger transaction with the firm now operates as an infrastructure development company. Over the previous decade Znomics had been a drug discovery company working on the zebrafish (Danio rerio) as a system to identify genes underlying human disease and to identify small molecule drugs affecting disease states. In November 2007, the firm merged with Pacific Syndicated Resources, Inc. (OTCBB:PSRI) and renamed the combined company as Znomics, Inc. under the leadership of the former Znomics' directors and officers. Znomics went on to create a catalogued library of mutations in the zebrafish, called the ZeneMark Library with over 11,000 strains of fish representing approximately half of the known genes. Znomics identified mutations in 107 human disease genes with plans to use the library to find new drug targets and develop human disease models in the fish.
